Underutilisation of ACE inhibitors in patients with congestive heart failure.
The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Abstract
Congestive heart failure (CHF) is associated with substantial morbidity and mortality, and is the only major cardiovascular disease increasing in prevalence. Despite abundant evidence to support their efficacy and cost-effectiveness, angiotensin-converting enzyme (ACE) inhibitors are sub-optimally used in patients with CHF. This paper reviews the evidence for the sub-optimal use of ACE inhibitors in patients with CHF, the factors contributing to this, and its implications for health systems. A systematic review of all articles assessing practice patterns (specifically the use of ACE inhibitors in CHF) identified by MEDLINE, search of bibliographies, and contact with content experts was undertaken. 37 studies have documented the use of ACE inhibitors in patients with CHF. Studies assessing use among all patients with CHF document 33% to 67% (median 51%) of all patients discharged from hospital and 10% to 36% (median 26%) of community dwelling patients were prescribed ACE inhibitors. Rates of ACE inhibitor use range from 43% to 90% (median of 71%) amongst those discharged from hospital having known systolic dysfunction, and from 67% to 95% (median of 86%) for those monitored in specialty clinics. Moreover, the dosages used in the 'real world' are substantially lower than those proven efficacious in randomised, controlled trials, with evaluations reporting only a minority of patients achieving target doses and/or an overall mean dose achieved to be less than one-half of the target dose. Factors predicting the use and optimal dose administration of ACE inhibitors are identified, and include variables relating to the setting (previous hospitalisation, specialty clinic follow-up), the physician (cardiology specialty versus family practitioner or general internist, board certification), the patient (increased severity of symptoms, male, younger), and the drug (lower frequency of administration). In light of the substantial evidence for reductions in morbidity and mortality, clearly, the prescription of ACE inhibitors is sub-optimal. Wide variability in ACE inhibitor use is noted, with higher rates consistently reported among patients having systolic dysfunction confirmed by an objective assessment--an apparent minority of the those having CHF. Optimisation of the prescription of proven efficacious therapies has the potential to confer a substantial reduction in the total cost of care for patients with CHF by reducing hospitalisations and lengths of hospital stays. It is likely that only multifaceted programs targeted toward the population at large will yield benefits to the healthcare system, given the widespread nature of the sub-optimal prescription of therapies proven effective in the management of patients with CHF.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is consistent with findings from prior studies42,43,44,45,46 of female patients in which guideline-directed therapies were initially adopted more slowly and underused among female patients.”
From Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US (2021) · cites this paper as [44]
Citations
Cites
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Swedberg, K., & Kjekshus, J. (1988) · The American Journal of Cardiology · doi:10.1016/s0002-9149(88)80087-0 · Cited by 3,762
(1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271003 · Cited by 3,725
The natural history of congestive heart failure: the Framingham study
McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971) · New England Journal of Medicine · doi:10.1056/nejm197112232852601 · Cited by 3,448
Cohn, J. N., Johnson, G., Ziesche, S., Cobb, F., Francis, G., Tristani, F., Smith, R., Dunkman, W. B., Loeb, H., Wong, M., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250502 · Cited by 2,833
Rich, M. W., Beckham, V., Wittenberg, C., Leven, C. L., Freedland, K. E., & Carney, R. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511023331806 · Cited by 2,328
Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation · doi:10.1161/01.cir.100.23.2312 · Cited by 1,244
COMMITTEE MEMBERS, WILLIAMS, J. F., BRISTOW, M. R., FOWLER, M. B., FRANCIS, G. S., GARSON, A., GERSH, B. J., HAMMER, D. F., HLATKY, M. A., LEIER, C. V., et al. (1995) · Circulation · doi:10.1161/01.cir.92.9.2764 · Cited by 663
Economic impact of heart failure in the United States: time for a different approach.
O'Connell, J. B., & Bristow, M. R. (1994) · PubMed · Cited by 653
Research works printed but not linked: 15
- Ackman, 1995, Prairie Med J, 65, 109
- Brophy, 1992, Can J Cardiol, 8, 495
- Johnstone, 1994, Can J Cardiol, 10, 613
- 1987, N Engl J Med, 316, 429
- Paul, 1994, Arch Intern Med, 154, 1143, 10.1001/archinte.1994.00420100129016 · doi:10.1001/archinte.1994.00420100129016 · Paper page
- 1999, Am J Cardiol, 83, 2A
- Croft, 1997, J Fam Pract, 44, 382
- Ghali, 1997, J La State Med Soc, 149, 474
- Houghton, 1997, J Royal Col Phys London, 31, 276
- Krumholz, 1997, Arch Intern Med, 157, 2242, 10.1001/archinte.1997.00440400092011 · doi:10.1001/archinte.1997.00440400092011 · Paper page
- Mair, 1996, Br J Gen Pract, 46, 77
- Parameshwar, 1992, J Royal Coll Phys London, 26, 139
- Parameshwar, 1992, Br J Gen Pract, 42, 287
- OReilly, 1999, CMAJ, 160, 1039
- McMurray, 1993, Br J Med Econ, 6, 91
Cited by
Appropriate prescribing in elderly people: how well can it be measured and optimised?
Spinewine, A., Schmader, K. E., Barber, N., Hughes, C., Lapane, K. L., Swine, C., & Hanlon, J. T. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61091-5 · Cited by 1,090
Eberly, L. A., Yang, L., Eneanya, N. D., Essien, U., Julien, H., Nathan, A. S., Khatana, S. A. M., Dayoub, E. J., Fanaroff, A. C., Giri, J., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6139 · Cited by 350
Koshman, S. L. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.7.687 · Cited by 336
Self-citationAnker, S. D., Kosiborod, M., Zannad, F., Piña, I. L., McCullough, P. A., Filippatos, G., van der Meer, P., Ponikowski, P., Rasmussen, H. S., Lavin, P. T., et al. (2015) · European Journal of Heart Failure · doi:10.1002/ejhf.300 · Cited by 183
Nieminen, M. S., Harjola, V.-P., Hochadel, M., Drexler, H., Komajda, M., Brutsaert, D., Dickstein, K., Ponikowski, P., Tavazzi, L., Follath, F., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2007.12.012 · Cited by 170
Metadata
- Authors
- Bungard, T. J., McAlister, F. A., Johnson, J. A., & Tsuyuki, R. T.
- Affiliations
- University of Alberta (CA)
- Corresponding author
- Tsuyuki, Ross T.
- Venue
- Drugs
- Published
- 2001
- Volume
- 61
- Issue
- 14
- Pages
- 2021-2033
- ISSN
- 0012-6667 (ISSN-L)
- OpenAlex
- W1980049759
- Cited by
- 73
- References
- 86
- Citations by year
- 2024: 1 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 3 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 2
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drugs (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
- Keywords
- congestive heart failure, ACE inhibitors, prescribing patterns, dose optimization, systolic dysfunction, health care costs, hospitalization, physician specialty, patient factors, medication adherence, quality of care, guideline adherence, community-dwelling patients, cost-effectiveness, multicomponent intervention, patient education
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Dose-Response Relationship, Drug, Drug Administration Schedule, Heart Failure, Humans, Morbidity, Practice Patterns, Physicians', Patient Selection, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Underutilisation of ACE inhibitors in patients with congestive heart failure. https://app.cochat.ai/papers/10.2165/00003495-200161140-00002
- The paper
- Bungard, T. J., McAlister, F. A., Johnson, J. A., & Tsuyuki, R. T. (2001). Underutilisation of ACE inhibitors in patients with congestive heart failure. Drugs. https://doi.org/10.2165/00003495-200161140-00002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.